Search

Meeting Coverage:

Aspen Retinal Detachment Society

ARDS: 2019

FOUNDERS LECTURE: Gene Therapy for Neovascular AMD 2019: Pitfalls and Promise

Allen C. Ho, MD, Timothy G. Murray, MD, MBA

Show Description +

Three failed gene therapy trials for neovascular AMD? Don't be discouraged, Allen C. Ho, MD, tells Timothy G. Murray, MD, MBA. Improvements in viral vectors, transgenes, and surgical delivery all point to improved prospects for treating patients with neovascular AMD.

Posted: 3/06/2019

Up Next

Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Mark W. Johnson, MD, Timothy G. Murray, MD, MBA

New Therapies in Wet AMD

New Therapies in Wet AMD

Peter K. Kaiser, MD, Timothy G. Murray, MD, MBA

ILM Peeling in Macular Hole Surgery: When and How

ILM Peeling in Macular Hole Surgery: When and How

David HW Steel, MBBS, FRCOphth, Timothy G. Murray, MD, MBA

TAYLOR SMITH AND VICTOR CURTIN LECTURE: The Essence of Diagnostic Ultrasonography

TAYLOR SMITH AND VICTOR CURTIN LECTURE: The Essence of Diagnostic Ultrasonography

Timothy G. Murray, MD, MBA, Yale L. Fisher, MD

Can We Modify the Natural History of Intermediate AMD?

Can We Modify the Natural History of Intermediate AMD?

Hugo Quiroz-Mercado, MD

Endophthalmitis: Clinical Cases and Management Strategies

Endophthalmitis: Clinical Cases and Management Strategies

Harry W. Flynn Jr, MD, Timothy G. Murray, MD, MBA

Vitreoretinal Surgery: When You Do What Others Won't

Vitreoretinal Surgery: When You Do What Others Won't

Timothy G. Murray, MD, MBA

Back to All Videos

FOUNDERS LECTURE: Gene Therapy for Neovascular AMD 2019: Pitfalls and Promise

Allen C. Ho, MD, Timothy G. Murray, MD, MBA

Three failed gene therapy trials for neovascular AMD? Don't be discouraged, Allen C. Ho, MD, tells Timothy G. Murray, MD, MBA. Improvements in viral vectors, transgenes, and surgical delivery all point to improved prospects for treating patients with neovascular AMD.

Posted: 3/06/2019

Please log in to leave a comment.

More From ARDS: 2019 Coverage

Can We Modify the Natural History of Intermediate AMD?

Can We Modify the Natural History of Intermediate AMD?

Hugo Quiroz-Mercado, MD

Endophthalmitis: Clinical Cases and Management Strategies

Endophthalmitis: Clinical Cases and Management Strategies

Harry W. Flynn Jr, MD, Timothy G. Murray, MD, MBA

Vitreoretinal Surgery: When You Do What Others Won't

Vitreoretinal Surgery: When You Do What Others Won't

Timothy G. Murray, MD, MBA

Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Mark W. Johnson, MD, Timothy G. Murray, MD, MBA

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARDS: 2019.